Skip to content
10-K

Annual Report

BioXcel Therapeutics, Inc. BTAI

0001104659-26-036214

← back to feed
Filed
Mar 27, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 27.07M sh
Shares Diluted FY 2025 · Dec 31, 2025 12.21M sh
Shares Diluted FY 2025 · Dec 31, 2024 2.54M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$57.62M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$72.03M
Long Term Debt FY 2025 · Dec 31, 2025 $84.66M
Long Term Debt FY 2025 · Dec 31, 2024 $102.51M
Short Term Debt FY 2025 · Dec 31, 2025 $24.93M
Short Term Debt FY 2025 · Dec 31, 2024 $0
Cash And Equivalents FY 2025 · Dec 31, 2025 $28.42M
Cash And Equivalents FY 2025 · Dec 31, 2024 $29.85M
Stockholders Equity FY 2025 · Dec 31, 2025 −$95.46M
Stockholders Equity FY 2025 · Dec 31, 2024 −$93.1M
Stockholders Equity FY 2025 · Dec 31, 2023 −$56.51M
Current Liabilities FY 2025 · Dec 31, 2025 $53.93M
Current Liabilities FY 2025 · Dec 31, 2024 $22.23M
Total Liabilities FY 2025 · Dec 31, 2025 $140.38M
Total Liabilities FY 2025 · Dec 31, 2024 $131.44M
Current Assets FY 2025 · Dec 31, 2025 $44.69M
Current Assets FY 2025 · Dec 31, 2024 $37.39M
Total Assets FY 2025 · Dec 31, 2025 $44.92M
Total Assets FY 2025 · Dec 31, 2024 $38.34M
Eps Diluted FY 2025 · Dec 31, 2025 −$5.73
Eps Diluted FY 2025 · Dec 31, 2024 −$23.51
Eps Basic FY 2025 · Dec 31, 2025 −$5.73
Eps Basic FY 2025 · Dec 31, 2024 −$23.51
Sga Expense FY 2025 · Dec 31, 2025 $20.49M
Sga Expense FY 2025 · Dec 31, 2024 $34.49M
Rd Expense FY 2025 · Dec 31, 2025 $30.25M
Rd Expense FY 2025 · Dec 31, 2024 $30.44M
Net Income FY 2025 · Dec 31, 2025 −$69.9M
Net Income FY 2025 · Dec 31, 2024 −$59.6M
Operating Income FY 2025 · Dec 31, 2025 −$50.46M
Operating Income FY 2025 · Dec 31, 2024 −$67.25M
Cost Of Revenue FY 2025 · Dec 31, 2025 $164K
Cost Of Revenue FY 2025 · Dec 31, 2024 $2.14M
Revenue FY 2025 · Dec 31, 2025 $642K
Revenue FY 2025 · Dec 31, 2024 $2.27M